ZX008 (Fenfluramine Hydrochloride) + Matching Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Dravet Syndrome

Conditions

Dravet Syndrome, Seizure Disorder

Trial Timeline

Jan 15, 2016 → Jul 29, 2020

NCT ID

NCT02682927

About ZX008 (Fenfluramine Hydrochloride) + Matching Placebo

ZX008 (Fenfluramine Hydrochloride) + Matching Placebo is a phase 3 stage product being developed by UCB for Dravet Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02682927. Target conditions include Dravet Syndrome, Seizure Disorder.

What happened to similar drugs?

2 of 11 similar drugs in Dravet Syndrome were approved

Approved (2) Terminated (3) Active (6)

🔄ZX008 (Fenfluramine Hydrochloride)UCBPhase 3

❌ZX008 (Fenfluramine Hydrochloride)UCBPhase 3

✅fenfluramineUCBApproved

🔄ZX008 (Fenfluramine Hydrochloride) + Matching PlaceboUCBPhase 3

🔄ZX008 (Fenfluramine Hydrochloride)UCBPhase 3

🔄fenfluramineUCBPhase 3

❌ClobazamLundbeckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02926898	Phase 3	Completed	Jan 27, 2017	Jun 5, 2018	Dravet Syndrome
NCT02682927	Phase 3	Completed	Jan 15, 2016	Jul 29, 2020	Dravet Syndrome

Competing Products

15 competing products in Dravet Syndrome

See all competitors

Product	Company	Stage	Hype Score
ZX008 (Fenfluramine Hydrochloride)	UCB	Phase 3	40
ZX008 (Fenfluramine Hydrochloride)	UCB	Phase 3	32
ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol	UCB	Phase 1	29
fenfluramine	UCB	Approved	50
Fenfluramine Hydrochloride	UCB	Pre-clinical	26
ZX008 (Fenfluramine Hydrochloride) + Matching Placebo	UCB	Phase 3	40
ZX008 (Fenfluramine Hydrochloride)	UCB	Phase 3	40
fenfluramine	UCB	Phase 3	44
Clobazam	Lundbeck	Phase 3	29
Clobazam + Placebo	Lundbeck	Phase 3	29
Epidiolex 100 mg/mL Oral Solution	Jazz Pharmaceuticals	Approved	47
zorevunersen	Stoke Therapeutics	Phase 3	41
STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses	Stoke Therapeutics	Phase 1/2	26
zorevunersen (STK-001)	Stoke Therapeutics	Phase 2	33
Clemizole HCl + Placebo	Harmony Biosciences	Phase 3	41